chufangao/CTO huggingface dataset:
Clinical trial NCT04334915: Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Official title: A Multicenter, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Industry supporter no longer supporting the study. Protocol A5415's study will run instead.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-22
Primary completion date: 2024-08-15
Completion date: 2024-08-15
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH
IPD access criteria: * With whom?~  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~* For what types of analyses?~  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.~* By what mechanism will data be made available?~  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT04429685: The Effects of Low Dose Ketamine on Cardiovascular Function
Official title: The Effects of Low Dose Ketamine on Cardiovascular Function
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The focus of the laboratory went a different direction given extramural funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02303951: Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
Official title: Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC
Acronym: NEO-VC
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The main reason for the early termination is the low recruitment rate.
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-01-22
Primary completion date: 2020-05-14
Completion date: 2020-05-14
Clinical trial NCT05973747: Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients
Official title: Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-19
Primary completion date: 2023-12-15
Completion date: 2023-12-15
Plan to share individual participant data: NO
Clinical trial NCT04320940: Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures
Official title: A Randomized, Double-Blind, Controlled Study to Assess the Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures
Sponsor: NEMA Research, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Insufficient participant recruitment hindered the study's progress, preventing robust data collection and compromising statistical power
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-12
Primary completion date: 2023-02-01
Completion date: 2023-02-01
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share IPD.
Clinical trial NCT02995330: Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Official title: A Pilot Study of Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: lack of accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-09
Primary completion date: 2021-06-16
Completion date: 2021-06-16
Plan to share individual participant data: NO
Clinical trial NCT03786419: A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Official title: Phase II Study to Evaluate the Efficacy and Safety of Atezolizumab in Subjects With Unresectable or Advanced Malignant Pleural Mesothelioma Who Experienced Progression on Platinum-Based Chemotherapy
Sponsor: Health Pharma Professional Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Publication of study results of ICI use in MPM as first line therapy
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-31
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT05268497: A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
Official title: Assessment of Feasibility of Using Clinician-Directed Cognitive Behavior Therapy Supplemented by a Digital Application in Conjunction With Esketamine (SPRAVATO®) in Participants With Treatment-Resistant Depression
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: due to budget decision and wanting to pursue other research priorities
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-01
Primary completion date: 2023-06-07
Completion date: 2023-06-07
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04615845: Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)
Official title: An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor: Pharmicell Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Difficult recruitment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-21
Primary completion date: 2022-02-15
Completion date: 2022-02-15
Clinical trial NCT03003364: Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury
Official title: A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury
Sponsor: Banc de Sang i Teixits (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-27
Primary completion date: 2019-07-25
Completion date: 2020-02-11
Plan to share individual participant data: NO
Clinical trial NCT03954444: A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream
Official title: A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product Oxymetazoline Hydrochloride Cream, 1% to Reference Product RHOFADETM Cream, 1% in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea
Sponsor: Actavis Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1105.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-04-15
Primary completion date: 2020-01-07
Completion date: 2020-02-27
Baseline population: Safety Population also defined as in the Participant Flow
Clinical trial NCT05601882: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Official title: A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)
Acronym: Level Up
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 926.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-28
Primary completion date: 2024-03-19
Completion date: 2024-08-08
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT05233410: Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
Official title: Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Acronym: TRuE-CHE2
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Business decision; no safety concerns
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-31
Primary completion date: 2024-04-25
Completion date: 2024-09-22
Plan to share individual participant data: NO
Clinical trial NCT02551679: ACP-01 in Patients With Critical Limb Ischemia
Official title: A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Sponsor: Hemostemix (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-08-31
Primary completion date: 2020-04-30
Completion date: 2021-04-30
Clinical trial NCT03277261: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Official title: Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Acronym: ULTIMATE 1
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 549.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-19
Primary completion date: 2020-07-23
Completion date: 2020-11-06
Baseline population: Intention-to-Treat (ITT) population consisted of all randomized participants.
Plan to share individual participant data: UNDECIDED
IPD sharing description: Data will be shared after study completion via publication.
Clinical trial NCT04473651: Safety and Tolerability of Lu AG06479 in Healthy Young Men
Official title: Interventional, Randomized, Double-blind, Placebo-controlled, Sequential-group, Single-ascending Oral Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of Lu AG06479 and Open-label Cross-over Study to Investigate Intra-subject Variability and Effect of Food in Healthy Young Men
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated for strategic reasons.
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-09
Primary completion date: 2021-11-10
Completion date: 2021-11-10
Clinical trial NCT04138875: A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Official title: A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-09-30
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03060772: A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)
Official title: A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)
Acronym: APPEAL
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was suspended in 2020 due to COVID-19 pandemic as a result of recruitment challenges and the inability to conduct all study procedures (e.g., bronchoscopy) per protocol. In late 2021 the decision was made to not re-open the study.
Enrollment: 50.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-01-03
Primary completion date: 2020-01-28
Completion date: 2020-01-28
Plan to share individual participant data: NO
Clinical trial NCT03239470: Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
Official title: A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of recruitment, ongoing and new feasibility issues, and the impact of the coronavirus infectious disease 19 (COVID-19) pandemic
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-10
Primary completion date: 2020-12-10
Completion date: 2023-01-09
Baseline population: Participants who donated peripheral blood to be processed in a lab that expanded regulatory T cells (Tregs) that, after two weeks, received a single infusion of ex vivo expanded autologous CD4+CD127lo/-CD25+ polyclonal Tregs (PolyTregs). Target cell dose was 1 x 10\^8 PolyTregs.
Limitations and caveats: Enrollment was stopped early, on May 1, 2020, due to:~* Lack of recruitment,~* Ongoing and new feasibility issues, including the recent approval of rituximab for treatment of pemphigus, and~* The impact of the coronavirus infectious disease 19 (COVID-19) pandemic.~No participants were enrolled in Cohort 2.
Plan to share individual participant data: YES
IPD sharing description: The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD time frame: On average, within 24 months after database lock for the trial.
IPD access criteria: Open access.
Clinical trial NCT04519658: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
Acronym: BrigHTN
Sponsor: CinCor Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 275.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-12
Primary completion date: 2022-06-14
Completion date: 2022-06-14
Clinical trial NCT02882321: Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Official title: Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory AML
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated by the Sponsor for apparent lack of effectiveness.
Enrollment: 17.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-09-29
Primary completion date: 2022-04-15
Completion date: 2022-04-15
Clinical trial NCT04237584: A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
Official title: ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients
Acronym: ESCALATE
Sponsor: MANA RBM (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.
Enrollment: 23.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-06-30
Primary completion date: 2022-03-07
Completion date: 2022-03-07
Limitations and caveats: ESCALATE (PC18-1005) was terminated early due to enrollment challenges.
Clinical trial NCT04091646: Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Official title: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 226.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-04
Primary completion date: 2020-08-18
Completion date: 2020-08-21
Plan to share individual participant data: NO
Clinical trial NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Official title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Acronym: AKITA
Sponsor: Guard Therapeutics AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment discontinued following DMC recommendation based on futility with regards to primary endpoint
Enrollment: 177.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-31
Primary completion date: 2023-04-15
Completion date: 2023-07-12
Baseline population: All dosed
Limitations and caveats: Study was stopped prematurely for futility following Data Monitoring Committee (DMC) recommendation.~The early termination lead to smaller numbers than planned, and that not all outcome measures were analyzed.
Plan to share individual participant data: NO
Clinical trial NCT02501434: Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
Official title: A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden
Acronym: ASTROH
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Enrollment: 88.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2023-01-31
Completion date: 2024-01-01
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share data other than through publication or requests to Robert James by other investigators.
Clinical trial NCT03022617: A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Official title: An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-31
Primary completion date: 2020-09-01
Completion date: 2022-09-29
Plan to share individual participant data: NO
Clinical trial NCT04419688: A First in Human Study of STT-5058, an Antibody That Binds ApoC3
Official title: A Double-blind, Randomised, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple-ascending Doses of Intravenously Administered STT-5058 in Otherwise Healthy Subjects With Elevated Triglyceride Levels and Single-ascending and Multiple Doses of Subcutaneously Administered STT-5058 in Otherwise Healthy Subjects With Elevated Triglyceride Levels and Patient Volunteers With Hypertriglyceridemia.
Sponsor: Staten Biotechnology BV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: recruitment failure
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-26
Primary completion date: 2022-12-23
Completion date: 2022-12-23
Plan to share individual participant data: NO
Clinical trial NCT04635774: Post Operative Delirium Study
Official title: Intranasal Insulin and Neurocognitive Function
Acronym: PODS
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Participants were unable to be enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-25
Primary completion date: 2023-11-14
Completion date: 2023-11-14
Plan to share individual participant data: NO
Clinical trial NCT03354897: Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension
Official title: Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension
Acronym: UMOD
Sponsor: NHS Greater Glasgow and Clyde (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 228.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-05
Primary completion date: 2021-10-30
Completion date: 2021-10-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04476030: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Official title: A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 440.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-09
Primary completion date: 2021-10-25
Completion date: 2021-12-22
Baseline population: Safety Set included all participants who administered blinded IP.
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/